Target Information

Target General Infomation
Target ID
T86192
Former ID
TTDI01791
Target Name
KCNQ voltage-gated potassium channel
Target Type
Clinical Trial
Disease Cancer pain; Fibromyalgia [ICD9:140-229, 338, 780, 729.1; ICD10: R52, G89, M79.7]
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0]
Drugs and Mode of Action
Drug(s) CNSB-001 Drug Info Phase 2 Neuropathic pain [548808]
Flupirtine Drug Info Phase 2 Cancer pain; Fibromyalgia [522237], [539675]
Agonist CNSB-001 Drug Info [530882]
Modulator Flupirtine Drug Info [544094]
Pathways
KEGG Pathway Adrenergic signaling in cardiomyocytes
Cholinergic synapse
Gastric acid secretion
Pancreatic secretion
Protein digestion and absorption
Vibrio cholerae infection
References
Ref 522237ClinicalTrials.gov (NCT00623415) Flupirtine as Oral Treatment in Multiple Sclerosis. U.S. National Institutes of Health.
Ref 539675(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2598).
Ref 548808Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029018)
Ref 530882The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J Peripher Nerv Syst. 2010 Mar;15(1):63-72.
Ref 544094Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 August; 157(7): 1241-1249.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.